Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Phase 2

Active, not recruiting

Conditions: NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)
NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

Interventions: Drug: Pembrolizumab

First Posted Date: 2018-11-02

Last Posted Date: 2024-12-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 19

Registration Number: NCT03728972

Locations: 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 7 locations

A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors

Phase 2

Active, not recruiting

Conditions: Breast Cancer
Hyposexual Desire Disorder

Interventions: Drug: Flibanserin Pill

First Posted Date: 2018-10-16

Last Posted Date: 2025-05-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 43

Registration Number: NCT03707340

Locations: 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 4 locations

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer
KRAS Gene Mutation

Interventions: Drug: Trametinib 2 mg
Drug: Trametinib 0.5 mg
Drug: Trametinib 1 MG
Drug: Trametinib 1.5 MG
Drug: Ponatinib 15 MG
Drug: Ponatinib 30 MG

First Posted Date: 2018-10-15

Last Posted Date: 2025-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT03704688

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity), Commack, New York, United States

and more 4 locations

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Phase 1

Active, not recruiting

Conditions: Primary Central Nervous System Lymphoma (PCNSL)
Secondary Central Nervous System Lymphoma (SCNSL)

Interventions: Drug: Ibrutinib
Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2018-10-11

Last Posted Date: 2025-03-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT03703167

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 4 locations

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia (AML)
Minimal Residual Disease

Interventions: Drug: Azacitidine
Drug: Avelumab

First Posted Date: 2018-10-09

Last Posted Date: 2019-02-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT03699384

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Phase 2

Completed

Conditions: Colorectal Cancer
Cholangiocarcinoma

Interventions: Device: Medtronic pump and Codman catheter
Drug: Floxuridine (FUDR)
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Irinotecan (CPT-11)
Drug: Fluorouracil
Drug: Anti-EGFR (Panitumumab or Cetuximab)

First Posted Date: 2018-10-03

Last Posted Date: 2024-07-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 35

Registration Number: NCT03693807

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Phase 2

Active, not recruiting

Conditions: Metastatic Cancer
Melanoma Cancer
Renal Cancer
Lung Cancer
Bladder Cancer
Head/Neck Cancers

Interventions: Radiation: Stereotactic Body Radiotherapy
Biological: Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab

First Posted Date: 2018-10-02

Last Posted Date: 2024-10-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 69

Registration Number: NCT03693014

Locations: 🇺🇸
Hartford Healthcare, Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 7 locations

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

Early Phase 1

Recruiting

Conditions: Central Nervous System Lymphoma

Interventions: Drug: Methotrexate
Drug: Rituximab
Drug: leucovorin
Drug: Glucarpidase

First Posted Date: 2018-09-26

Last Posted Date: 2025-05-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT03684980

Locations: 🇺🇸
Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 7 locations

RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

Phase 1

Completed

Conditions: Advanced Non-small Cell Lung Cancer

Interventions: Drug: RO5126766

First Posted Date: 2018-09-24

Last Posted Date: 2024-07-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 15

Registration Number: NCT03681483

Locations: 🇺🇸
Miami Cancer Institute, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Lehigh Valley Health Network, Allentown, Pennsylvania, United States

Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship

Active, not recruiting

Conditions: Breast Cancer Survivors

Interventions: Behavioral: Traditional Neurocognitive Assessments
Behavioral: Online Cognitive Battery (Cogsuite)

First Posted Date: 2018-09-17

Last Posted Date: 2024-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 441

Registration Number: NCT03674437

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy